share_log

海正药业(600267.SH):磷酸奥司他韦原料药获得《化学原料药上市申请批准通知书》

Haizheng Pharmaceutical (600267.SH): Oseltamivir phosphate API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”

Gelonghui Finance ·  Feb 28 04:47

Gelonghui, Feb. 28: Haizheng Pharmaceutical (600267.SH) announced that Haizheng Pharmaceutical Nantong Co., Ltd., a wholly-owned subsidiary, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for oseltamivir phosphate APIs approved and issued by the State Drug Administration on February 28, 2024. Oseltamivir phosphate is a precursor to its active metabolite (oseltamivir carboxylate). Oseltamivir carboxylate is a selective influenza virus neuraminidase inhibitor used in the treatment of influenza A and B in adults and children 1 year and older, and the prevention of influenza A and B in adults and adolescents aged 13 and over.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment